BioWorld MedTech

March 30, 2016

China's Venus Medtech maintains lead in market for cardiac valve products

HONG KONG — Leading investment bank Goldman Sachs Group Inc. has injected $37 million into Chinese medical device company Venus Medtech (Hangzhou) Inc. after the creation of the first specialized cardiac valve research institute in China. Read More

Cancer paves the road for other companion diagnostics, but still a long way to go

Doc societies see six months of DAPT for latest DES devices

Cairn finds its way on difficult FDA pathway, launches gastric emptying breath test

Other news to note

Daily M&A

Financings

Appointments and advancements

Product briefs

MDD'S Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for Jan 5, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 5, 2026.

AND-017 increases RBC and hemoglobin in sickle cell disease

BioWorld Science

Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...

3D rendering of antibody drug conjugated with cytotoxic payload

ADCs’ breakout 2025 and their still-unfinished potential

BioWorld Science

Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...

Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact

BioWorld

Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...